Skip to main content
SpringerLink
Log in

Rotigotine

In Parkinson’s Disease

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

  • ▲ Rotigotine is a nonergolinic dopamine D3/D2/D1 receptor agonist delivered via a transdermal system and has been evaluated for the treatment of idiopathic Parkinson’s disease.

  • ▲ Patients with early Parkinson’s disease receiving rotigotine monotherapy experienced significantly greater improvements in parkinsonian symptoms (as measured by Unified Parkinson’s Disease Rating Scale scores) compared to placebo in two large, well designed clinical trials. Significant beneficial effects versus placebo were observed with the 30 and 40 cm2 rotigotine patches in both trials.

  • ▲ Patients with advanced Parkinson’s disease receiving rotigotine as adjunctive therapy with levodopa experienced clinically significant reductions from baseline in ‘off’ time in two well designed clinical trials. In one trial, a large placebo effect was observed, therefore, there was no significant difference between placebo and active treatment (20, 40 and 60 cm2) for this primary efficacy variable, However, a recent study found a significant (p ≤ 0.003) reduction in ‘off’ time in rotigotine 40 and 60 cm2 recipients versus that in the placebo group.

  • ▲ Rotigotine was generally well tolerated in clinical trials as both monotherapy and when administered with levodopa; adverse events were generally mild or moderate in severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Neupro® is the proposed trade name for the rotigotine transdermal system that has been submitted to regulatory authorities. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 2004 May 29; 363(9423): 1783–93

    Article  PubMed  CAS  Google Scholar 

  2. Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurology 2004 May; 3(5): 309–16

    Article  PubMed  Google Scholar 

  3. Chan KL, Jagait P, Tugwell C. Parkinson’s disease: current and future aspects of drug treatment. Hospital Pharmacist 2004; 11(1): 18–22

    Google Scholar 

  4. Stiasny-Kolster K, Kohnen R, Schollmayer E, et al. and The Rotigotine SP 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004; 19(12): 1432–8

    Google Scholar 

  5. Stiasny-Kolster K, Garcia-Borreguero D, Saletu B, et al. Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome — a double-blind placebo-controlled multi-center dose-finding study [abstract no. P1242 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  6. Schwarz Pharma. Current development projects: Parkinson’s disease [online]. Available from URL: http://www.schwarzpharma.com [Accessed 2005 Oct 4]

  7. Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 2005 Jul 26; 65(2 Suppl. 1): S3–5

    Article  PubMed  CAS  Google Scholar 

  8. Calabrese VP, Lloyd KA, Brancazio P, et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of Parkinsonism. Mov Disord 1998 Sep; 13(5): 768–74

    Article  PubMed  CAS  Google Scholar 

  9. Belluzzi JD, Domino EF, May JM, et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov Disord 1994 Mar; 9(2): 147–54

    Article  PubMed  CAS  Google Scholar 

  10. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson’s disease. Expert Opin Invest Drugs 2003 Aug; 12(8): 1335–52

    Article  CAS  Google Scholar 

  11. Chase TN, Verhagen Metman L, Bravi D, et al. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson’s disease. Clin Neuropharmacol 1995; 18Suppl. 1: S207–15

    Article  Google Scholar 

  12. Kehr J, Scheller DKA. Continuous delivery of rotigotine leads to continuous dopamine receptor stimulation in a rat model [abstract no. P1285 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  13. Lebsanft HB, Scheller DKA, Heindl M, et al. Effect of continuous administration of rotigotine in a rat model of dyskinesia [abstract no. P297]. Mov Disord 2005; 20Suppl. 10: S89 plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)

    Google Scholar 

  14. Scheller DKA, Heindl M, Schmidt W. Continuous administration of rotigotine does not induce dyskinesia in a rat model of PD [abstract no. P1262 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  15. Scheller DK, Smith L., Breidenbach A, et al. Effect of rotigotine on locomotor activity and disability scores in MPTP-treated common marmosets following subcutaneous administration [abstract no. P396]. Mov Disord 2004; 19Suppl. 9: S145 plus poster presented at the 8th International Congress of Parkinson’s Disease and Movement Disorders; 2004 Jun 14–17; Rome

    Google Scholar 

  16. Schneider JS, McLaughlin WW, Roeltgen DP. Anti-Parkinson effects of the selective dopamine D-2 agonist N-0923 in hemi-Parkinsonian monkeys [abstract no. 1002P]. Neurology 1992 Apr; 42(4 Suppl. 3): 443

    Google Scholar 

  17. Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation [abstract no. 250]. Ann Neurol 2004; 56Suppl. 8: S54 plus poster presented at the 129th Annual Meeting of the American Neurological Association; 2004 Oct 3–6; Toronto (ON)

    Google Scholar 

  18. Stichel CC, Scheller DKA. Rotigotine prevents neurodegeneration in a mouse model of Parkinson’s disease [abstract no. P1286 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  19. Timmerman W, Rusk IN, Tepper P, et al. The effects of enantiomers of the dopamine agonist N-0437 on food consumption and yawning behaviour in rats. Eur J Pharmacol 1989 Dec 12; 174: 107–14

    Article  PubMed  CAS  Google Scholar 

  20. Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001 May; 16: 459–63

    Article  PubMed  CAS  Google Scholar 

  21. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003 Dec; 60(12): 1721–8

    Article  Google Scholar 

  22. Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract no. 102]. J Clin Pharmacol 2005; 45(9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11–13; Rockville (MD)

    Google Scholar 

  23. Braun M, Cawello W, Poole K, et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease [abstract no. P1245 plus poster]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  24. Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine [abstract no. 101]. J Clin Pharmacol 2005; 45(9): 1091 plus poster presented at the 34th Annual Meeting of the American College of Clinical Pharmacology; 2005 Sep 11–13; Rockville (MD)

    Google Scholar 

  25. Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa [abstract no. 4775 plus poster]. 16th International Congress on Parkinson’s Disease and Related Disorders; 2005 June 5–9; Berlin

  26. Watts RL, Wendt J, Nausieda PL, et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson’s disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial [abstract no. P737]. Mov Disord 2004 Jun 14; 19Suppl. 9: S258 plus poster presented at the 8th International Congress of Parkinson’s Disease and Movement Disorders; 2004 Jun 14–17; Rome

    Google Scholar 

  27. Quinn N. for the SP 511 Investigators. Rotigotine transdermal delivery system (TDS) (SPM 962) — a multicenter, double-blind, randomized, placebo-controlled trial to asses the safety and efficacy of rotigotine TDS in patients with advanced Parkinson’s disease [abstract no. P-TU-223]. Parkinsonism Relat Disord 2001; 7Suppl. 1: S66 plus poster presented at the 14th International Congress on Parkinson’s Disease; 2001 Jul 27–Aug 1; Helsinki

    Google Scholar 

  28. LeWitt PA, Chang F-L, Fazzini E, et al. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson’s disease [abstract no. SC115]. 9th Congress of the European Federation of Neurological Societies; 2005 Sep 17–20; Athens

  29. Babic T, Boroojerdi B, Randerath O, et al. Rotigotine CDS patch in advanced-stage, idiopathic Parkinson’s disease: a parallel group, open-label, dose-escalation trial [abstract no. P05.095]. Neurology 2004 Apr 13; 62(7 Suppl. 5): A399

    Google Scholar 

Download references

Acknowledgements

At the request of the journal, SCHWARZ PHARMA AG provided a non-binding review of this article.

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Neil A. Reynolds, Keri Wellington & Stephanie E. Easthope

Authors
  1. Neil A. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keri Wellington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie E. Easthope
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil A. Reynolds.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reynolds, N.A., Wellington, K. & Easthope, S.E. Rotigotine. CNS Drugs 19, 973–981 (2005). https://doi.org/10.2165/00023210-200519110-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200519110-00006

Keywords

Search

Navigation